Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
333
-
Total 13F shares, excl. options
-
97.5M
-
Shares change
-
+1.87M
-
Total reported value, excl. options
-
$2.04B
-
Value change
-
+$40.6M
-
Put/Call ratio
-
0.87
-
Number of buys
-
183
-
Number of sells
-
-126
-
Price
-
$20.87
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2024
373 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2024.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 333 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 97.5M shares
of 123M outstanding shares and own 79.13% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (19.4M shares), VANGUARD GROUP INC (8.43M shares), STATE STREET CORP (5.8M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.13M shares), DIMENSIONAL FUND ADVISORS LP (3.01M shares), Pacer Advisors, Inc. (2.96M shares), GOLDMAN SACHS GROUP INC (2.8M shares), RENAISSANCE TECHNOLOGIES LLC (2.71M shares), GEODE CAPITAL MANAGEMENT, LLC (2.67M shares), and FIRST TRUST ADVISORS LP (2.23M shares).
This table shows the top 333 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.